Deferiprone therapy for transfusional iron overload

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 2 SPEC. ISS., 2005, Pages 299-317

  Hoffbrand, A V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Deferiprone; Desferrioxamine; Iron chelation; Iron overload; Thalassaemia major

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; LIVER ENZYME;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTHROPATHY; ARTICLE; BLOOD TRANSFUSION; CHONDROPATHY; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG STRUCTURE; DRUG WITHDRAWAL; EYE TOXICITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEART FAILURE; HEART INJURY; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OTOTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFRACTORY ANEMIA; SKIN DISEASE; THALASSEMIA MAJOR; VOMITING; ZINC DEFICIENCY;

EID: 14544288577     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.026     Document Type: Review

References (68)

1. R.C. Hider S. Singh J.B. Porter E.R. Huehns The development of hydroxypyridin-4-ones as orally active iron chelators In A. Bank 4th Cooley's Anemia Symposium, Annals of the New York Academy of Sciences vol. 612 1990 327-328
2. D.Y. Liu Z.D. Liu R.C. Hider Oral iron chelators - development and application Clinical Haematology 15 2002 369-384
3. G.J. Kontoghiorghes A.V. Hoffbrand Prospects for effective and oral chelation in transfusional iron overload Recent Advances in Haematology 5 1988 75-98
4. F.N. Al-Refaie A.V. Hoffbrand Oral iron chelation therapy Recent Advances in Haematology 7 1993 185-216
5. G.J. Kontoghiorges M.A. Aldouri L. Sheppard et al. 1-2-dimethyl-3-hydroxypyrid-4-one an orally active chelator for treatment of iron overload Lancet i 1987 1294-1295
6. G.J. Kontoghiorges M.A. Aldouri A.V. Hoffbrand et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one British Medical Journal 295 1987 1509-1512
7. J.A. Barman Balfour R.H. Foster Deferiprone: A review of its clinical potential in iron overload in alpha thalassaemia major and other transfusion-dependent diseases Drugs 3 1999 553-578
8. A.V. Hoffbrand A. Cohen C. Hershko Role of deferiprone in chelation therapy for transfusional iron overload Blood 102 2003 17-24
9. A. Maggio P. Rigano P. Renda V. Salvo Oral chelators in thalassaemia syndrome In A. Maggio A.V. Hoffbrand (eds.) Clinical Aspects and Therapy of Thalassemia 2004 233-270
10. D. Matsui J. Klein C. Hermann et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia Clinical and Pharmacological Therapeutics 50 1991 294-298
11. F.N. Al-Refaie L.N. Shephard P. Nortey et al. Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload British Journal of Haematology 89 1995 403-408
12. A.F. Collins F.F. Fassos S. Stobie et al. Iron-balance and dose-response studies of the oral irn chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease Blood 83 1994 2329-2333
13. R.W. Grady V. Berdoukas E.A. Rachmilewitz et al. Iron chelation therapy: metabolic aspects of combining deferiprone and deferoxamine (abstract). 11th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases Catania 2001 74-78
14. R.W. Grady V. Berdoukas E.A. Rachmilewitz et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion (abstract) Blood 100 2002 241
15. G.J. Kontoghiorghes A.N. Bartlett A.V. Hoffbrand et al. Long-term trial with the oral iron chelator 1,2-dimethyl-s-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies British Journal of Haematology 76 1990 295-300
16. K.P. Hoyes J.B. Porter Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects dilution of intracellular iron pools British Journal of Haematology 85 1993 393-400
17. O. Shalev T. Repka A. Goldfarb et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells from both in vitro and in vivo Blood 86 1995 2008-2013
18. L. de Franchesi O. Shalev A. Piga et al.Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl co-transport activity Journal of Laboratory and Clinical Medicine 133 1999 64-69
19. P. Pootrakul P. Sirankapracha J. Sankote et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand British Journal of Haematology 122 2003 305-310
20. 14 C-deferiprone in normal, thalassaemic and sickle red blood cells British Journal of Haematology 105 1999 1081-1083
21. N.F. Olivieri G.M. Brittenham D. Matsui et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major New England Journal of Medicine 332 1995 918-922
22. N.F. Olivieri G.M. Brittenham C.E. McLaren et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major New England Journal of Medicine 339 1998 417-423
23. R. Fischer F. Largo P. Nielson et al. Monitoring long-term efficacy of iron chelatio therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: Application of SQUID biomagnetic liver susceptometry British Journal of Haematology 121 2003 938-948
24. A. Maggio G.D. D'Amico A. Morabito et al. Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial Blood Cells, Molecules and Diseases 28 2002 196-208
25. L.J. Anderson N. Wonke E. Prescott et al. Improved myocardial iron levels and ventricular function with oral deferiprone compared with subcutaneous desferrioxamine in thalassemia Lancet 360 2002 516-520
26. N.F. Olivieri D.G. Nathan J.H. MacMillan et al. Survival in medically treated patients with homozygous β-thalassemia New England Journal of Medicine 331 1994 574-578
27. G.M. Brittenham P.M. Griffith A.W. Nienhuis et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major New England Journal of Medicine 331 1994 567-573
28. P.D. Jensen F.T. Jenset T. Christensen et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool Blood 101 2003 4632-4639
29. L. Anderson S. Holden B. Boris et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload European Heart Journal 22 2001 2171-2179
30. N.F. Olivieri N. Beluzzo M. Mucara et al. Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassemia major during long-term therapy with the orally active iron chelating agent Blood 84 1994 109a
31. C.T. Peng K.C. Chow J.H. Chen et al. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan European Journal of Haematology 70 2003 392-397
32. A. Piga C. Gaglioti E. Fogliacco F. Tricta Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major Haematologica 70 2003 489-496
33. A.V. Hoffbrand F. Al-Refaie B. Davis et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients Blood 91 1998 295-300
34. A. Ceci P. Baiardi M. Felisi et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients British Journal of Haematology 118 2002 330-336
35. V. Gabutti A. Piga Results of long-term iron chelating therapy Acta Haematologica 95 1996 26-36
36. B. Modell M. Khan M. Darlison Survival in beta thalassaemia major in the United Kingdom: Data from the U.K. Thalassaemia Register Lancet 355 2000 2051-2052
37. L. Anderson N. Bunce B. Davis et al. Reversal of siderotic cardiomyopathy: A prospective study with cardiac magnetic resonance (MR) Heart supplement 1 2001 33
38. J.B. Porter R.D. Abeysinghe L. Marshall et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 1996 705-713
39. K.-H. Wu J.S. Chang C.V.H. Tsai C.T. Peng Combined therapy with deferiprone and desferrioxamine successfully regresses heart failure in patients with β-thalassemia major Annals of Hematology 83 2004 471-473
40. C. Hershko M.D. Cappellini R. Galanello et al. Purging iron from the heart British Journal of Haematology 125 2004 545-551
41. N.F. Olivieri G. Koren C. Hermann et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients Lancet 336 1990 1275-1279
42. M.B. Agarwal S.S. Gupte C. Viswanathan et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial British Journal of Haematology 82 1992 460-466
43. B. Wonke C. Wright A.V. Hoffbrand Combined therapy with deferiprone and desferrioxamine British Journal of Haematology 103 1998 361-364
44. Taher A, Taha M, Hoffbrand AV. et al. (submitted).
45. W. Breuer M.J.J. Empers P. Pootrakul et al. Deferoxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy Blood 97 2001 792-798
46. G. Link A.M. Konijn W. Breuer et al. Exploring the 'iron shuttle' hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture Journal of Laboratory and Clinical Medicine 138 2001 130-138
47. B.P. Esposito W. Breuer P. Sirankapracha et al. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation Blood 102 2003 2670-2677
48. F.H. Mourad A.V. Hoffbrand M. Sheikh-Taha et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients British Journal of Haematology 121 2003 187-189
49. A.V. Hoffbrand A.N. Bartlett P.A. Veys et al. Agranulocytosis and thrombocytopenia in a patient with Blackfan-Diamond anaemia during oral chelator trial Lancet ii 1989 457
50. A.R. Cohen R. Galanello A. Piga et al. Safety profile of the oral iron chelator deferiprone: A multicenter study British Journal of Haematology 108 2000 305-312
51. A. Cohen R. Galanello A. Piga et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 2003 1583-1587
52. F.N. Al-Refaie B. Wonke A.V. Hoffbrand Deferiprone-associated myelotoxicity European Journal of Haematology 53 1994 298-301
53. F.N. Al-Refaie C. Hershko A.V. Hoffbrand et al. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on oral iron chelators British Journal of Haematology 91 1995 224-229
54. J.M. Cunningham F.N. Al-Refaie A.E. Hunter et al. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro European Journal of Haematology 52 1994 176-179
55. A.N. Bartlett A.V. Hoffbrand G.J. Kontoghiorghes Long term trial with the oral iron chelator 1-2-dimethyl-3-hydroxypyrid-4-one (L1).II. Clinical observations British Journal of Haematology 76 1990 301-304
56. A. Castriota-Scanderbeg M. Sacco Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone) British Journal of Haematology 96 1997 254-255
57. F.N. Al-Refaie B. Wonke D.G. Wickens et al. Zinc concentration in patients with iron overload receiving iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or deferoxamine Journal of Clinical Pathology 47 1994 657-660
58. F.N. Al-Refaie B. Wonke A.V. Hoffbrand et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major Blood 80 1992 593-599
59. F. Callea Iron chelation with oral deferiprone in patients with thalassemia (letter) New England Journal of Medicine 339 1998 1711-1719
60. M. Stella G. Pinzello A. Maggio Iron chelatiion with oral deferiprone in patients with thalassemia (letter) New England Journal of Medicine 339 1998 1712
61. P. Tondury A. Zimmermann P. Nielsen et al. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients British Journal of Haematology 101 1998 413-415
62. A.P. Piga S. Facello C. Gaglioti et al. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation Blood 92 1998 216
63. R. Galanello De Virgilis A. Agus et al. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major In 9th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases. Hamburg, Germany 1999 pp. 50
64. V. Berdoukas T. Bohane C. Eagle et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1) Transfusional Science 23 2000 239-240
65. A. Wanless G. Sweeney A.P. Dhillon et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 2002 1566-1569
66. A. Taher E. Aoun A.I. Sharra et al. Five year trial of deferiprone chelation therapy in thalassemia major patients Acta Haematologica 2004 in press
67. A. Mangiagli V. De Sanctis S. Campisi et al. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine Journal of Pediatric Endocrinology & Metabolism 13 2000 677-680
68. B. Lesic J. Foulton E. Carniel Comparisons of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica Antimicrobial Agents and Chemotherapy 46 2002 1741-1745